Literature DB >> 16737845

Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes.

A Rostedt Punga1, K Ahlqvist, E Bartoccioni, F Scuderi, M Marino, A Suomalainen, H Kalimo, E V Stålberg.   

Abstract

OBJECTIVE: To compare the electrophysiological and histopathological features of immunological myasthenia gravis (MG) subtypes.
METHODS: Fifty MG patients underwent clinical examination, MuSK-Ab and AChR-Ab analysis. The majority underwent quantitative and single-fiber electromyography (QEMG, SFEMG), repetitive nerve stimulation and deltoid muscle biopsy. From muscle specimens with histological mitochondrial dysfunction, we amplified mitochondrial DNA (mtDNA). In specimens with mtDNA deletions, the nuclear gene POLG1 was sequenced.
RESULTS: Five AChR-Ab seropositive [AChR(+)] and 5 seronegative [AChR(-)] patients were MuSK-Ab seropositive [MuSK(+)]. Five of 7 neurophysiologically examined MuSK(+) patients (71%) had proximal myopathic pattern, compared to 7 of 31 MuSK(-)/AChR(+) patients (23%) (P=0.012). SFEMG was abnormal in all examined MuSK(+) patients. All 7 biopsied MuSK(+) and 32 MuSK(-) patients (89%) had cytochrome c oxidase (COX) negative fibers. Three of five MuSK(+) and 13 of 20 MuSK(-) patients analyzed had multiple mtDNA deletions but no POLG1 mutations.
CONCLUSIONS: Similar degree of SFEMG abnormalities was present in proximal muscles among MuSK(+) and AChR(+) patients. Proximal myopathy was over-represented in MuSK(+) patients; however, both MuSK(+) and MuSK(-) patients had mild myopathy with frequent mitochondrial abnormalities. SIGNIFICANCE: The weakness in MuSK(+) patients is most likely due to disturbed neuromuscular transmission. The frequently encountered mitochondrial dysfunction in MG warrants further study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16737845     DOI: 10.1016/j.clinph.2006.03.028

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  12 in total

Review 1.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Modulation of the W748S mutation in DNA polymerase gamma by the E1143G polymorphismin mitochondrial disorders.

Authors:  Sherine S L Chan; Matthew J Longley; William C Copeland
Journal:  Hum Mol Genet       Date:  2006-11-06       Impact factor: 6.150

3.  Electrodiagnostic Characteristics Suggestive of Muscle-Specific Kinase Myasthenia Gravis.

Authors:  Michael Skolka; Christopher J Lamb; Devon I Rubin; Christopher J Klein; Ruple S Laughlin
Journal:  Neurol Clin Pract       Date:  2022-06

4.  Effect of sera from seronegative myasthenia gravis patients on neuromuscular junctions.

Authors:  Rumi Sato; Shiho Imamoto; Iku Utsnomiya; Terumasa Chiba; Kyoji Taguchi; Kenji Abe; Keiko Tanaka; Tadashi Miyatake
Journal:  Neurol Sci       Date:  2013-02-07       Impact factor: 3.307

5.  Switch to double positive late onset MuSK myasthenia gravis following thymomectomy in paraneoplastic AChR antibody positive myasthenia gravis.

Authors:  Berit Jordan; Susanne Schilling; Stephan Zierz
Journal:  J Neurol       Date:  2015-12-08       Impact factor: 4.849

6.  Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies.

Authors:  Giovanna Cenacchi; Valentina Papa; Papa Valentina; Marina Fanin; Fanin Marina; Elena Pegoraro; Pegoraro Elena; Corrado Angelini; Angelini Corrado
Journal:  J Neurol       Date:  2010-11-19       Impact factor: 4.849

Review 7.  The mitochondrial biogenesis signaling pathway is a potential therapeutic target for myasthenia gravis via energy metabolism (Review).

Authors:  Lingling Ke; Qing Li; Jingwei Song; Wei Jiao; Aidong Ji; Tongkai Chen; Huafeng Pan; Yafang Song
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

8.  Treatment of MuSK-Associated Myasthenia Gravis.

Authors:  Khalid El-Salem; Ahmed Yassin; Kefah Al-Hayk; Salma Yahya; Duha Al-Shorafat; Said S Dahbour
Journal:  Curr Treat Options Neurol       Date:  2014-04       Impact factor: 3.972

9.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077

10.  Fatigue and muscle atrophy in a mouse model of myasthenia gravis is paralleled by loss of sarcolemmal nNOS.

Authors:  Sarina Meinen; Shuo Lin; Markus A Rüegg; Anna Rostedt Punga
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.